Don’t let the high cost of brand meningococcal quadrivalent conjugate vaccine disrupt your protection against meningococcal disease. We help eligible patients access Menquadfi (meningococcal ACWY conjugate vaccine) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Menquadfi Patient Assistance Program helps eligible patients access this meningococcal ACWY vaccine at little or no cost when meeting income, insurance, and clinical criteria. Under ACA, most privately insured have vaccine coverage without cost-sharing.
At AffordMyPrescriptions, our Patient Advocates handle the entire Menquadfi PAP enrollment for a flat $69.95 per month — so you never face a gap in your meningococcal immunization.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Menquadfi enrollment — so you never face a gap in your meningococcal disease prevention.
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| ACA / VFC / Medicare $0 | $0 | Covered without cost-share |
| Walgreens | ~$180/dose | Save substantially |
| CVS Pharmacy | ~$200/dose | Save substantially |
| Walmart | ~$160/dose | Save substantially |
| Costco | ~$150/dose | Save substantially |
| Menveo (alt MenACWY) | ~$170/dose | Alt MenACWY vaccine |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Menquadfi — independent of dosage or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Menquadfi Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Under ACA, ACIP-recommended vaccines including meningococcal ACWY are covered without cost-sharing for privately insured. VFC provides free vaccines for eligible children. Serogroup B vaccination (Bexsero, Trumenba) is separate for at-risk adolescents/young adults.
Complete a simple eligibility form so our team can determine if you may qualify for Menquadfi assistance.
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Once approved, your Menquadfi is delivered through the assistance program while we manage refills and annual renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Menquadfi:
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $150–$200/dose even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Fixed $69.95/month — never changes regardless of retail price
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Menquadfi assistance.
Menquadfi is a meningococcal ACWY conjugate vaccine — protecting against Neisseria meningitidis serogroups A, C, W, and Y. Meningococcal disease is rare but rapidly fatal — vaccination is especially important for adolescents/young adults, at-risk populations, and travelers to endemic regions.
How It Works:
Neisseria meningitidis (meningococcus) causes invasive meningococcal disease — meningitis (headache, fever, stiff neck), septicemia (rapidly fatal shock, purpura fulminans), or both. Case fatality is ~10–15% even with treatment; survivors often have severe sequelae (limb amputation, deafness, cognitive impairment). It is rare in absolute numbers but devastating. Higher risk in adolescents/young adults, college students in dorms, military recruits, complement deficiency, asplenia, HIV, and travelers to the sub-Saharan African ‘meningitis belt’ during dry season. Menquadfi is a conjugate vaccine — linking meningococcal capsular polysaccharides for serogroups A, C, W, and Y to a carrier protein (tetanus toxoid) — eliciting a durable T-cell-dependent immune response with memory. Boosters are effective for revaccination. Meningococcal serogroup B is a separate vaccine (Bexsero, Trumenba).
Form and Use:
Menquadfi 0.5 mL IM injection in the deltoid. ACIP schedule: routine dose at 11–12 years, booster at 16 years. Persons 2 years and older with certain conditions or exposures per ACIP. Given at pharmacy, clinic, or pediatrician’s office.
Generic Availability:
No generic Menquadfi. Similar meningococcal ACWY conjugate vaccine: Menveo (brand — GSK; MenACWY-CRM conjugate). Meningococcal serogroup B vaccines: Bexsero (brand), Trumenba (brand) — for adolescents 10–25 years at increased risk. Under ACA, ACIP-recommended vaccines including meningococcal vaccination are covered without cost-sharing by insurance. Vaccines for Children (VFC) provides free vaccines to eligible children through 18. Medicare Part D vaccine coverage. State/local health departments. Sanofi Pasteur Patient Assistance Program.
Warnings:
Anaphylaxis and severe allergic reactions (rare — do not administer to persons with severe allergic reaction to prior meningococcal vaccine, tetanus toxoid, or components), Guillain-Barré syndrome (temporal association possible after MenACWY vaccine — weigh risk-benefit), immunocompromised persons (may have reduced immune response), embryo-fetal considerations. Other: injection site pain, redness, swelling; fatigue, headache, myalgia, fever. Not a live vaccine — safe for immunocompromised patients from a live-vaccine safety standpoint, though immune response may be reduced.
$150–$200 per dose at pharmacies. Menveo (alternative MenACWY) is similarly priced. Under ACA, ACIP-recommended vaccines are covered without cost-sharing for privately insured. VFC provides free vaccines for eligible children through 18.
Adolescents at 11–12 years (routine) with a booster at 16 years (ACIP schedule). At-risk populations 2 years and older: college freshmen in residential housing, military recruits, complement deficiency, functional or anatomic asplenia (sickle cell disease, splenectomy), HIV infection, travelers to the sub-Saharan African meningitis belt, occupational exposure.
MenACWY (Menquadfi) covers serogroups A, C, W, Y. Serogroup B is a separate vaccine (Bexsero, Trumenba). ACIP: MenB vaccination for adolescents 16–23 years (preferred 16–18) with shared clinical decision-making; recommended for persons 10+ at increased risk. Meningitis B outbreaks on college campuses have raised its importance.
Rare but devastating — invasive meningococcal disease has ~10–15% case fatality even with prompt treatment; survivors often have severe long-term sequelae (limb amputation, deafness, cognitive impairment). It progresses rapidly from healthy to critically ill within hours. Prevention through vaccination is far preferable to treating established disease.
Injection site pain, redness, swelling; fatigue, headache, myalgia, fever. Serious reactions rare — anaphylaxis (extremely rare), Guillain-Barré (temporal association possible). Not a live vaccine — safe for immunocompromised persons from a live-vaccine standpoint.
Meningococcal vaccination prevents rare but rapidly fatal disease — accessible immunization saves lives. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.